E2XE34 logo

Exelixis BOVESPA:E2XE34 Stock Report

Last Price

R$58.98

Market Cap

R$36.0b

7D

15.2%

1Y

n/a

Updated

24 Mar, 2024

Data

Company Financials +

E2XE34 Stock Overview

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

E2XE34 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance4/6
Financial Health6/6
Dividends0/6

Exelixis, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Exelixis
Historical stock prices
Current Share PriceUS$58.98
52 Week HighUS$58.98
52 Week LowUS$50.71
Beta0.53
1 Month Change15.15%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Changen/a
Change since IPO21.80%

Recent News & Updates

Recent updates

Shareholder Returns

E2XE34BR BiotechsBR Market
7D15.2%-0.1%0.04%
1Yn/a3.0%22.4%

Return vs Industry: Insufficient data to determine how E2XE34 performed against the BR Biotechs industry.

Return vs Market: Insufficient data to determine how E2XE34 performed against the BR Market.

Price Volatility

Is E2XE34's price volatile compared to industry and market?
E2XE34 volatility
E2XE34 Average Weekly Movementn/a
Biotechs Industry Average Movement9.2%
Market Average Movement4.5%
10% most volatile stocks in BR Market8.0%
10% least volatile stocks in BR Market2.3%

Stable Share Price: E2XE34 has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine E2XE34's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
19941,310Mike Morrisseyhttps://www.exelixis.com

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors.

Exelixis, Inc. Fundamentals Summary

How do Exelixis's earnings and revenue compare to its market cap?
E2XE34 fundamental statistics
Market capR$36.04b
Earnings (TTM)R$1.04b
Revenue (TTM)R$9.15b

34.7x

P/E Ratio

3.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
E2XE34 income statement (TTM)
RevenueUS$1.83b
Cost of RevenueUS$72.55m
Gross ProfitUS$1.76b
Other ExpensesUS$1.55b
EarningsUS$207.77m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)0.69
Gross Margin96.04%
Net Profit Margin11.35%
Debt/Equity Ratio0%

How did E2XE34 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.